Hypoparathyroidism

Hypoparathyroidism is a disorder of insufficient parathyroid hormone (PTH) secretion, leading to hypocalcemia, hyperphosphatemia, and disrupted calcium homeostasis. Unlike the more common secondary hyperparathyroidism (elevated PTH from chronic hypocalcemia), hypoparathyroidism is characterized by inappropriately low or absent PTH in the setting of hypocalcemia.

Epidemiology:

• Prevalence: 70,000-90,000 cases in the United States (rare disorder)
• Post-surgical: 75% of cases are iatrogenic following thyroid or parathyroid surgery
• Permanent post-thyroidectomy: 1-2% of total thyroidectomies, higher after reoperative or central neck dissection (up to 10%)
• Autoimmune: 15-20% of cases, often part of polyglandular syndrome
• Genetic/congenital: 5-10%, includes DiGeorge syndrome

PTH Physiology Review

Normal PTH functions:

Net result of PTH deficiency: Low serum calcium, high serum phosphate, low urine calcium

Causes of Hypoparathyroidism

Pathophysiology of Hypocalcemia

Hypocalcemia mechanisms:

Acute Hypocalcemia Presentation

Physical Examination Signs

Chronic Hypoparathyroidism Manifestations

Algorithm

View larger

Acute Hypocalcemia Management

Chronic Hypoparathyroidism Management

Preoperative Optimization

Intraoperative Management

Postoperative Management

The post-surgical section and Viva Scenario 2 (a post-parathyroidectomy patient) treat all post-operative hypocalcaemia as PTH deficiency, and the biochemical differential table lists causes of hypocalcaemia - but it never names the other major post-operative mechanism, which is biochemically the mirror image: hungry bone syndrome (HBS).

• What it is. After parathyroidectomy for severe or long-standing hyperparathyroidism (or occasionally after thyroidectomy for thyrotoxicosis with high-turnover bone), the abrupt fall in PTH removes the drive to bone resorption while osteoblastic bone formation continues. The demineralised, high-turnover "hungry" skeleton avidly re-mineralises, taking up calcium, phosphate AND magnesium from the circulation - producing profound, prolonged hypocalcaemia (often for days to weeks).
• How it differs from surgical hypoparathyroidism (the key exam point).
  • Hungry bone syndrome: low calcium, LOW phosphate, low magnesium, HIGH alkaline phosphatase (ongoing bone formation), and PTH normal or appropriately elevated/recovering.
  • Surgical hypoparathyroidism: low calcium, HIGH phosphate, LOW or undetectable PTH, and low/normal alkaline phosphatase (low-turnover state).
  • The phosphate direction (low in HBS, high in hypoparathyroidism) and the PTH level separate them at the bedside.
• Risk factors for HBS: severe pre-operative hyperparathyroidism (very high PTH and calcium), radiological/biochemical bone disease (osteitis fibrosa cystica, high alkaline phosphatase), large adenoma or parathyroid carcinoma, older age and vitamin D deficiency.
• Management: aggressive and prolonged calcium (large intravenous then oral) plus activated vitamin D, with magnesium and phosphate repletion, continued until the skeleton re-mineralises. Crucially, HBS is self-limiting as the bone re-fills - unlike permanent hypoparathyroidism.

The intra-operative section notes that "citrated blood products can chelate calcium", but never develops it - even though this is the orthopaedic surgeon's commonest encounter with acute hypocalcaemia (revision arthroplasty, pelvic and spine surgery, polytrauma resuscitation).

• Mechanism. Stored blood products contain citrate anticoagulant, which chelates ionised calcium. Normally the liver rapidly metabolises citrate (to bicarbonate), so ordinary-rate transfusion causes no problem. But with rapid, massive transfusion (roughly one blood volume, or faster than the liver can clear citrate - worsened by hypothermia, hepatic impairment or the low hepatic flow of shock) citrate accumulates and ionised calcium falls, giving the same tetany, QT-prolongation and myocardial-depression risks as any hypocalcaemia.
• Measure ionised, not total, calcium. Citrate lowers ionised calcium while total calcium can read normal or even high (citrate-bound), so only an ionised calcium detects it - a classic pitfall.
• Amplified in hypoparathyroidism. A patient with hypoparathyroidism has no PTH reserve to defend calcium, so citrate load during major surgery hits harder and faster - anticipate and pre-empt it.
• Management. During massive transfusion, monitor ionised calcium and give intravenous calcium (calcium chloride or gluconate) to keep it normal - the "calcium" limb of the lethal-triad / massive-transfusion protocols - and keep the patient warm to preserve citrate clearance. (Detailed transfusion protocols belong to the blood-loss-management topic; the point here is the calcium mechanism.)

Global Epidemiology

• Prevalence: roughly 25-40 per 100,000 population in Western registry data; defined as an orphan/rare disease in Europe and the US
• Dominant cause worldwide: post-surgical, accounting for around 75% of chronic cases; permanent hypoparathyroidism follows about 1-3% of total thyroidectomies and more after central neck dissection or reoperation
• Non-surgical causes (autoimmune, genetic, infiltrative, hypomagnesaemia-related) predominate in regions with lower thyroid-surgery volumes and in paediatric cohorts
• Idiopathic/non-surgical disease is relatively more represented in South Asian and Middle Eastern series, where it presents with prominent basal ganglia calcification and seizures

Major Guidelines Side by Side

Registry and Database Signals

National registries are emerging rather than mature for hypoparathyroidism, but population datasets are informative. Danish national-registry cohorts (Underbjerg and colleagues) link postsurgical disease to excess infection and neuropsychiatric morbidity and to increased renal stones/insufficiency in idiopathic disease, while showing no overall fracture excess despite high bone mineral density. The international PARADIGHM observational registry tracks long-term outcomes and PTH-replacement safety across multiple countries.

High- vs Limited-Resource Practice Variation

• High-resource settings: intraoperative or early postoperative PTH-guided protocols, ionised calcium assays, calcitriol availability, and access to PTH analogues (rhPTH 1-84 / palopegteriparatide) for refractory disease
• Limited-resource settings: reliance on total serum calcium with albumin correction, plain (parent) vitamin D or alfacalcidol where calcitriol is scarce, and greater burden of late-presenting idiopathic disease with established basal ganglia calcification, cataract and seizures
• Universal priorities: surgeon experience and meticulous parathyroid preservation remain the single most effective preventive measure regardless of resource level

• Is PTH replacement disease-modifying? rhPTH(1-84) and the long-acting prodrug palopegteriparatide reduce calcium/calcitriol requirements and improve biochemistry, but whether they prevent hard endpoints (renal impairment, basal ganglia calcification, fractures) is unproven. PTH analogues also carry a historical osteosarcoma class warning from rodent data.
• Optimal calcium target: guidelines recommend low-normal calcium, yet no trial links any specific target to clinical outcomes. The balance between symptom relief and hypercalciuria/nephrocalcinosis is individualised.
• Phosphate versus calcium control: calcium-phosphate product, not calcium alone, drives basal ganglia and ectopic calcification, but routine phosphate-lowering strategies are not standardised.
• Bone paradox: bone mineral density is high and fracture risk is not increased in cohort data, but bone is low-turnover with abnormal microarchitecture; the true fracture and quality implications remain debated.
• Defining "permanent": the 6- versus 12-month threshold after thyroidectomy varies between studies, inflating heterogeneity in reported incidence.
• Routine post-thyroidectomy PTH protocols: early PTH measurement can triage supplementation and discharge, but cost-effectiveness and the best cut-offs differ between surgical units.